Diagnostic delays and Undertreatment of Psoriatic Arthritis New research from the University of Bath in the UK reveals delayed diagnosis and undertreatment of psoriatic arthritis often results in irreversible damage to joints. https://t.co/AyaxUXJs8n https://t.co/9x9GhnTR1Y

• Diagnostic delays and Undertreatment of Psoriatic Arthritis | RheumNow

1st Line Biologics vs. csDMARDs in Adult Still's Disease A German multicentre, retrospective study assessed the first-line efficacy of biologics and conventional synthetic DMARD therapy in patients with adult-onset Still's disease (AOSD) and found biologic agents were https://t.co/NaxACbmyxl

Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or https://t.co/mCsz88JACh

Patient Education handout on Carpal Tunnel Syndrome https://t.co/NMRKGeE7Po https://t.co/LYnTlfJBcZ

• Carpal Tunnel Syndrome (CTS)

Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24 https://t.co/0Ra8eUeBOi https://t.co/0dwOSxjVxs

• TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly re…

Matched cohort study of 83,811 #RA pts showed RA had a 12% increased risk of avoidable hospitalizations (CHF, pulmonary edema; (IRR 1.12). Predictors of ACSC hosp. were age, Steroids, ambulatory comorbid Dxs. ambulatory care access & ^ primary care may reduce this risk. https://t.co/AxQVoXoxxx

Topline results from Phase 3b APEX study, comparing guselkumab to placebo in biologic naive #PsA pts - showed significant improvement by ACR20 and significantly less Xray progression of structural damage (vs PB) at Week 24 https://t.co/7sY1sX9B3O https://t.co/EislRI5WAy

• TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly re…

FDA announced approval of Inebilizumab (Uplizna; Amgen), 1st approved Rx for IgG4-related disease (targets CD19+ B cells). IG4-related Dz is estimated to affect 20,000 in the USA. List price is $140,248.50 per dose, After two initial loading doses it is given q 6 mos. https://t.co/zHD2Yv3PjI

#RheumTwitter—Heading to the highly anticipated State-of-the-Art Clinical Symposium (SOTA), April 4-6, in Chicago? Share your meeting experience on social & be sure to include #SOTA25 in your posts. We can’t wait to see you there! https://t.co/HZTZUm2UfG

• https://x.com/ACRheum/status/1907787444277202981/photo/1

📢 Federal funding for lupus research and the Lupus Research Program within the Department of Defense hang in the balance as Congress debates spending priorities. 🔬 Investing in lupus research – and all medical research – is one of the wisest investments we can make. That’s why https://t.co/OgWo5z0fMB

• https://x.com/LupusResearch/status/1907823935082700915/photo/1

🎉 Today's Annual Scientific Conference kicked off with The CARRA Registry Retreat! The retreat brought together physician-PIs, research coordinators, research managers and patients/caregivers involved with the CARRA Registry. 💙 #CARRA2025 #pedsrheum https://t.co/GYYHAjsIdK

• https://x.com/carrainc/status/1907885597806489750/photo/1

Systematic review 21 studies showed potential of RTX with IVIg in autoimmune Dz - 10 studies on pemphigus (85 pts) - all Positive outcomes except 1 paraneoplastic pemphigus. Infections (eg, P. jirovecii pneumonia) seen in 3. 11 studies (24 pts) Rx'd neuropathies, CND lupus& https://t.co/o0RRUBIqmS

Commemorating the 15th Anniversary of the Biologics Price Competition and Innovation Act (by Dr. Sara Yim, FDA) - BPCIA enacted March 23, 2010 - created pathway for biosimilar approvals - Now ~70 FDA approved biosimilars; 18 in 2024 https://t.co/dhST5vAJyT https://t.co/BWefr7k9hh

• Expert discusses the Biologics Price Competition and Innovation Act